Velan Capital Investment Management LP Has $773,000 Position in Avalo Therapeutics, Inc. $AVTX

Velan Capital Investment Management LP raised its position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 38.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 154,972 shares of the company’s stock after purchasing an additional 43,000 shares during the period. Avalo Therapeutics makes up about 0.8% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 25th biggest holding. Velan Capital Investment Management LP owned about 1.18% of Avalo Therapeutics worth $773,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. RWA Wealth Partners LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at $2,505,000. Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics by 19.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company’s stock worth $5,264,000 after buying an additional 106,389 shares during the period. Nantahala Capital Management LLC bought a new position in Avalo Therapeutics during the first quarter worth about $7,209,000. ADAR1 Capital Management LLC acquired a new position in Avalo Therapeutics in the first quarter valued at about $80,000. Finally, Allostery Investments LP increased its holdings in shares of Avalo Therapeutics by 46.1% in the first quarter. Allostery Investments LP now owns 107,141 shares of the company’s stock worth $858,000 after acquiring an additional 33,827 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AVTX shares. HC Wainwright boosted their price objective on Avalo Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Cantor Fitzgerald started coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Tuesday, October 14th. Cowen started coverage on shares of Avalo Therapeutics in a research report on Friday, September 5th. They issued a “buy” rating on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Monday, September 29th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.67.

Avalo Therapeutics Stock Down 1.0%

Shares of AVTX stock opened at $19.24 on Wednesday. Avalo Therapeutics, Inc. has a 12 month low of $3.39 and a 12 month high of $20.45. The company’s fifty day simple moving average is $16.36 and its 200-day simple moving average is $10.55. The firm has a market cap of $348.82 million, a PE ratio of -3.59 and a beta of 0.84.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.52). On average, equities analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.